Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

21.43USD
17 Sep 2019
Change (% chg)

-- (--)
Prev Close
$21.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,314,361
52-wk High
$39.59
52-wk Low
$16.64

Latest Key Developments (Source: Significant Developments)

Mylan Expands Oncology Portfolio With Launch Of Generic Faslodex Injection
Tuesday, 17 Sep 2019 

Sept 17 (Reuters) - Mylan NV ::MYLAN EXPANDS ONCOLOGY PORTFOLIO WITH LAUNCH OF GENERIC FASLODEX® INJECTION, A TREATMENT FOR ADVANCED BREAST CANCER.MYLAN - ANNOUNCED U.S. LAUNCH OF FULVESTRANT INJECTION, A GENERIC VERSION OF ASTRAZENECA'S FASLODEX INJECTION.  Full Article

Mylan NV Says Director Robert Coury Reports Open Market Purchase Of 49,859 Ordinary Shares At Average Price Of $20.06Per Share On August 2
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Mylan NV ::MYLAN NV SAYS DIRECTOR ROBERT COURY REPORTS OPEN MARKET PURCHASE OF 49,859 ORDINARY SHARES AT AVERAGE PRICE OF $20.06PER SHARE ON AUGUST 2 - SEC FILING.  Full Article

Mylan to begin search for CFO of new company
Monday, 29 Jul 2019 

July 29 (Reuters) - Mylan NV ::MYLAN SEES POTENTIAL FOR SHARE REPURCHASES BY THE END OF 2021 - CONF. CALL.PFIZER CEO SAYS MYLAN HAS BEEN "SIGNIFICANTLY UNDERVALUED", EXPECTS NEW COMBINATION TO ADDRESS THIS - CONF. CALL.MYLAN SAYS WILL BEGIN SEARCH FOR CFO FOR NEW COMPANY, WHOSE APPOINTMENT WILL BE AGREED UPON WITH PFIZER- CONF. CALL.HEAD OF NEW COMPANY, MICHAEL GOETTLER, SAYS WILL BE OPERATING THROUGH GLOBAL CENTERS IN PITTSBURGH, PENNSYLVANIA; SHANGHAI, CHINA AND HYDERABAD, INDIA- CONF. CALL.HEAD OF NEW COMPANY MICHAEL GOETTLER SAYS ONLY ABOUT A THIRD OF NEW COMPANY REVENUE TO COME FROM GENERICS- CONF. CALL.HEAD OF NEW COMPANY MICHAEL GOETTLER SAYS ROUGHLY 55% OF ITS REVENUE WILL COME FROM NORTH AMERICA AND EUROPE, REST FROM ASIA AND EMERGING MARKETS - CONF. CALL.MYLAN PRESIDENT RAJIV MALIK SAYS NEW COMPANY EXPECTS ABOUT $3 BILLION IN REVENUE FROM PRODUCTS EXPECTED TO LAUNCH BY 2023- CONF. CALL.OUTGOING MYLAN CFO KEN PARKS SAYS IN NEAR TERM, NEW COMPANY ANTICIPATES TOTAL REVENUE TO GROW MODESTLY AS GROWTH WILL OFFSET EXPECTED PRICING PRESSURE - CONF. CALL.MYLAN EXPECTS EXPECT "STRONG CASH FLOWS" IN THE SECOND HALF OF THE YEAR- CONF. CALL.PFIZER CFO EXPECTS GROWTH WILL START "EARLIER" POST CLOSING MYLAN DEAL, SOME TIME IN 2020 - CONF. CALL.ROBERT COURY, EXECUTIVE CHAIRMAN OF NEW COMPANY, SAYS LOOKING FOR SOMEONE WHO IS AN EXISTING PUBLIC COMPANY CFO WITH "QUITE A BIT OF EXPERIENCE" TO FILL ROLE OF FINANCE CHIEF FOR NEW COMPANY- CONF. CALL.  Full Article

FDA Says Approved Mylan’S Generic Diclofenac Sodium
Wednesday, 19 Jun 2019 

June 19 (Reuters) - FDA::FDA SAYS APPROVED MYLAN’S GENERIC DICLOFENAC SODIUM.  Full Article

Biocon Says Health Canada Approved Co And Mylan's Cancer Drug
Wednesday, 22 May 2019 

May 22 (Reuters) - Biocon Ltd ::HEALTH CANADA APPROVES BIOCON AND MYLAN'S OGIVRI™, FIRST TRASTUZUMAB BIOSIMILAR, FOR TREATMENT OF HER2-POSITIVE BREAST AND GASTRIC CANCERS.  Full Article

Mylan NV Says Does Not See Accelerated Price Erosion In U.S. Generics Market
Wednesday, 8 May 2019 

May 7 (Reuters) - Mylan NV ::MYLAN EXEC SAYS WE HAVE ALREADY LAUNCHED 2/3RD OF PRODUCTS NEEDED TO HIT OUR $1 BILLION SALES TARGET FROM NEW LAUNCHES - CONF CALL .MYLAN NV EXEC SAYS DOES NOT EXPECT 2019 TO BENEFIT FROM PRODUCT REVIEW PROCESS; SEES BENEFIT FROM 2020 AND BEYOND - CONF CALL.MYLAN NV EXEC SAYS NEW PRODUCT LAUNCHES BROUGHT IN $250 MILLION DURING THE QUARTER - CONF CALL.MYLAN NV EXEC SAYS DOES NOT SEE ACCELERATED PRICE EROSION IN U.S. GENERICS MARKET; SEES TRENDS SIMILAR TO 2018 - CONF CALL.  Full Article

Mylan says Some States Intend To File Complaint Against Co for "Anticompetitive Conduct"
Tuesday, 7 May 2019 

May 7 (Reuters) - Mylan NV ::MYLAN - IN MAY 2019, ATTORNEYS GENERAL FROM SOME STATES NOTIFIED MYLAN THEY INTEND TO FILE NEW COMPLAINT AGAINST CO.MYLAN - COMPLAINT ALLEGES "ANTICOMPETITIVE CONDUCT" FROM CO WITH RESPECT TO ADDITIONAL GENERIC DRUGS.  Full Article

Mylan Institutional LLC Initiates Voluntary Recall Of Levoleucovorin Injection
Monday, 18 Mar 2019 

March 18 (Reuters) - MYLAN INSTITUTIONAL LLC ::MYLAN INSTITUTIONAL LLC INITIATES VOLUNTARY NATIONWIDE RECALL OF LEVOLEUCOVORIN INJECTION DUE TO THE PRESENCE OF PARTICULATE MATTER.MYLAN INSTITUTIONAL LLC - CONDUCTING VOLUNTARY NATIONWIDE RECALL OF TWO LOTS OF LEVOLEUCOVORIN INJECTION, 250 MG/25 ML TOTHE CONSUMER/USER LEVEL.MYLAN INSTITUTIONAL LLC - RECALLED LOTS WERE MANUFACTURED BY ALIDAC PHARMACEUTICALS LIMITED AND DISTRIBUTED BY MYLAN INSTITUTIONAL LLC.MYLAN INSTITUTIONAL LLC - LEVOLEUCOVORIN INJECTION IS BEING RECALLED DUE TO PRESENCE OF PARTICULATE MATTER IDENTIFIED AS COPPER SALTS.MYLAN INSTITUTIONAL LLC - TO DATE, MYLAN HAS NOT RECEIVED ANY REPORTS OF ADVERSE EVENTS RELATED TO THE RECALL.  Full Article

Mylan NV Says Chief Legal Officer Daniel Gallagher Informed Co Of His Intention To Return To Private Practice
Tuesday, 12 Feb 2019 

Feb 11 (Reuters) - Mylan NV ::MYLAN NV - DANIEL GALLAGHER, MYLAN'S CHIEF LEGAL OFFICER, INFORMED MYLAN OF HIS INTENTION TO RETURN TO PRIVATE PRACTICE.  Full Article

Mylan Announces U.S. Launch Of Mesalamine Rectal Suppository, 1000 mg
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Mylan NV ::MYLAN ADDS FIRST GENERIC FOR CANASA® RECTAL SUPPOSITORY TO GROWING GASTROENTEROLOGY PORTFOLIO.MYLAN NV - MESALAMINE RECTAL SUPPOSITORY HAS 180 DAYS OF GENERIC DRUG EXCLUSIVITY.MYLAN NV - ANNOUNCED U.S. LAUNCH OF MESALAMINE RECTAL SUPPOSITORY, 1000 MG, FIRST GENERIC VERSION OF ALLERGAN'S CANASA RECTAL SUPPOSITORY, 1000 MG.  Full Article

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta

The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta.